SPHINX |
Catalog No.GC65981
One-Click Copy Product Info
|
SPHINX est un inhibiteur sélectif de SRPK1 avec une valeur IC50 de 0,58 μM. SPHINX réduit efficacement la néovascularisation choroÏdienne (CNV) in vivo. SPHINX peut être utilisé pour la recherche de la DMLA (dégénérescence maculaire liée À l'Âge).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 848057-98-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
IC50: 0.58 μM (SRPK1)[1]
SPHINX is a selective SRPK1 inhibitor with an IC50 value of 0.58 μM. SPHINX effectively reduces Choroidal Neovascularization (CNV) in vivo. SPHINX can be used for the research of (age-related macular degenaration) AMD[1].
SPHINX (10 μM; 2 h) affects EGF-induced phosphorylation of SRSF1 and SRSF2[1].
SPHINX (5 μM; 24 h) reduces the expression of VEGF165 relative to GAPDH control either in primary RPE and ARPE-19 cell lines[1].
Western Blot Analysis[1]
| Cell Line: | ARPE-19 cell line |
| Concentration: | 10 μM |
| Incubation Time: | 2 hours |
| Result: | Blocked EGF-induced phosphorylation of SRSF1 and SRSF2. |
SPHINX (10 ng; i.o. on laser photocoagulation day 0 and day 7) affects neovascular growth in vivo[1].
SPHINX (25 ng; i.o. on laser photocoagulation day 0 and day 7) affects the CNV area in CNV rats[1].
| Animal Model: | C57/B6 mice with laser-induced CNV[1] |
| Dosage: | 10 ng |
| Administration: | Intraocular injection; 10 ng on laser photocoagulation day 0 and day 7 |
| Result: | Significantly reduced neovascular growth compared with saline-injected controls. |
| Animal Model: | Norway Brown rats with laser-induced choroidal neovascularization[1] |
| Dosage: | 25 ng (10 ng/uL) |
| Administration: | Intraocular injection; 25 ng (10 ng/uL) on laser photocoagulation day 0 and day 7 |
| Result: | Significantly reduced the CNV area compared with saline injected controls. |
| Cas No. | 848057-98-7 | SDF | |
| Formula | C17H17F3N2O3 | M.Wt | 354.32 |
| Solubility | DMSO : 50 mg/mL (141.12 mM; ultrasonic and warming and heat to 60°C) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8223 mL | 14.1115 mL | 28.2231 mL |
| 5 mM | 564.5 μL | 2.8223 mL | 5.6446 mL |
| 10 mM | 282.2 μL | 1.4112 mL | 2.8223 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)